Long‐term outcomes of patients treated with rituximab as second‐line treatment for adult immune thrombocytopenia – Follow‐up of the RITP study
Open Access
- 27 April 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 191 (3), 460-465
- https://doi.org/10.1111/bjh.16672
Abstract
RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, we provide the duration of response, splenectomy and mortality rates based on extended follow‐up after completion of the RITP study. Extended follow‐up data were retrospectively collected for 72 (83%) patients out of the 84 patients who were not splenectomized during the initial RITP study. For the present analysis, median [interquartile range] duration of follow‐up after randomization was 72 [62–82] months. Median duration of response among patients who achieved an initial response was significantly longer in patients who received rituximab (8·2 [5·5–16·7] months) as compared to placebo (1·8 [1·3–3·6] months), P = 0·036. Overall, 35 patients underwent splenectomy (13 in the rituximab, and 22 in the placebo arm, P = 0·12). Eleven patients (10%) died during the study: five in the rituximab and six in the placebo arms, including four deaths from severe bleeding. Although most rituximab‐treated patients eventually relapsed, a longer duration of response and a trend towards lower splenectomy rate were observed in rituximab‐treated patients.This publication has 14 references indexed in Scilit:
- American Society of Hematology 2019 guidelines for immune thrombocytopeniaBlood Advances, 2019
- Updated international consensus report on the investigation and management of primary immune thrombocytopeniaBlood Advances, 2019
- Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐rituxAmerican Journal of Hematology, 2019
- Immune ThrombocytopeniaThe New England Journal of Medicine, 2019
- Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?Haematologica, 2019
- Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentBlood, 2012
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopeniaBlood, 2012
- Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 studyBlood, 2008